Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape
Episode 4, Oct 02, 07:52 PM
To view the article and claim CE credit for this activity, click here.
Eosinophilic esophagitis (EoE) is a chronic inflammatory condition of the esophagus that can substantially impact patients' quality of life. Early diagnosis and intervention are critical for mitigating the clinical burden of EoE and improving long-term prognosis. This supplement to The American Journal of Managed Care reviews recent advances in the treatment of EoE, focusing on the potential of recently approved therapies to improve patient outcomes. Data from recent clinical trials and updated guideline recommendations highlight the progress made in targeting the histology and symptomatology of the disease. Important managed care considerations, including financial challenges and treatment access issues, that arise from the introduction of these novel therapies will be examined. Pharmacists and managed care professionals will gain insights into the inflammatory process of EoE and the importance of early treatment while optimizing health care resource utilization. The article provides an analysis of clinical data to support the safe and effective use of new therapies, as well as potential opportunities for improving treatment decision-making and resource allocation in the management of EoE.
Eosinophilic esophagitis (EoE) is a chronic inflammatory condition of the esophagus that can substantially impact patients' quality of life. Early diagnosis and intervention are critical for mitigating the clinical burden of EoE and improving long-term prognosis. This supplement to The American Journal of Managed Care reviews recent advances in the treatment of EoE, focusing on the potential of recently approved therapies to improve patient outcomes. Data from recent clinical trials and updated guideline recommendations highlight the progress made in targeting the histology and symptomatology of the disease. Important managed care considerations, including financial challenges and treatment access issues, that arise from the introduction of these novel therapies will be examined. Pharmacists and managed care professionals will gain insights into the inflammatory process of EoE and the importance of early treatment while optimizing health care resource utilization. The article provides an analysis of clinical data to support the safe and effective use of new therapies, as well as potential opportunities for improving treatment decision-making and resource allocation in the management of EoE.